Sionna Therapeutics is trading at $3.51, down 5.90% in pre-market; no new company-specific announcement or clear overnight catalyst was identified. - The latest company release was a November 2 investor-conference announcement, which does not explain the decline. - Biotech was reported up 2.08% pre-market, while the earlier SION-719 trial failure is material background—not a fresh November 5 event. - Premarket volume and trading-activity details were unavailable in the sources reviewed.